Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Arylsulfatase A gene therapy - REGENXBIO

Drug Profile

Arylsulfatase A gene therapy - REGENXBIO

Latest Information Update: 16 Dec 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ReGenX Biosciences
  • Developer Assistance Publique Hopitaux de Paris
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Metachromatic leukodystrophy

Most Recent Events

  • 16 Dec 2015 No development reported - Phase-I/II for Metachromatic leukodystrophy in France (Intracerebral)
  • 01 Mar 2013 Phase-I/II clinical trials in Metachromatic leukodystrophy in France (Intracerebral)
  • 20 Dec 2011 Preclinical trials in Metachromatic leukodystrophy in USA (Intracerebral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top